If you’ve noticed fewer people grabbing fast food lately, you’re not imagining things. Analysts now point to the Ozempic impact—a shift in appetite, eating habits, and social routines—as a real threat to fast-food chains. McDonald’s U.S. same-store sales dropped 3.6% in Q1, a harsh sign that fewer visits equal less revenue. Redburn Atlantic issued a rare “Sell” rating, citing GLP-1 drugs like Ozempic as a key factor in reshaping consumer behavior. Let’s break down five ways this weight-loss revolution is squeezing the Burger King of value.
Why the Ozempic Impact Is Hitting McDonald’s Now
